AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-33298315_ITM" title="Facts and information about Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal(R) Technology.">Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal(R) Technology.</a>

Close Set up an RSS feed that alerts you when new articles from Business Wire are available.

Frequently asked questions about RSS feeds

Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal(R) Technology.

Business Wire

| October 29, 2007 | COPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

DUBLIN, Ireland -- Elan Corporation, plc (NYSE: ELN) today announced that Johnson & Johnson Pharmaceutical Research & Development, L.L.C (J&JPRD) has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for paliperidone palmitate, an investigational, once-monthly atypical antipsychotic intramuscular injection for the treatment of schizophrenia and the prevention of recurrence of the symptoms of schizophrenia. Paliperidone palmitate is a long acting injectable ester of the active ingredient in INVEGA[TM]1 and utilizes Elan's NanoCrystal[R] Technology.

Under the terms of Elan's License Agreement, Elan is eligible to receive payments upon the achievement of certain milestones. Additionally, Elan will receive…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


MAP Pharmaceuticals Announces Expanded Development Agreement with Elan Drug...: Press release article from: PR Newswire July 27, 2005 700+ words
...expand our collaboration with Elan Drug Technologies. As an emerging specialty...budesonide is a proprietary Elan innovation for poorly water...Executive Vice President, Elan Drug Technologies said, "We are very pleased...


MAP Pharmaceuticals announces expanded development agreement with Elan Drug...: News wire article from: Asia Africa Intelligence Wire July 27, 2005 700+ words
...announced that MAP Pharmaceuticals and Elan Corp plc have agreed to amend their previous...agreement, signed in 2004, to seek to apply Elan's proprietary NanoCrystal technology...Pharmaceuticals has been collaborating with Elan to develop a nebulized form of budesonide...


Elan Signs License Agreement with Abbott for Elan's Proprietary NanoCrystal(R)...: Press release article from: Business Wire July 6, 2006 700+ words
...patients", commented Paul V. Breen, Executive Vice President and Head, Elan Drug Technologies. About NanoCrystal(R) Technology and Elan Drug Technologies Elan's NanoCrystal technology is a proven, robust, drug optimization technology...


Elan Reports Fourth Quarter and Full-Year 2008 Results.: Press release article from: Business Wire February 10, 2009 700+ words
...business units--Biopharmaceuticals and Elan Drug Technologies." Mr. Martin added that Elan remains committed to building the leading...full-year 2008 while revenue from the Elan Drug Technologies (EDT) business increased by 2% for


Elan and EntreMed Execute License Agreement for Proprietary NanoCrystal(R)...: Press release article from: PR Newswire January 10, 2006 700+ words
...Executive Vice President, Elan Drug Technologies, said, "We are pleased...to third party clients. Elan Drug Technologies offers its technology based...More information about Elan Drug Technologies broad range of technologies...


Elan Announces Further Alignment of Resources as Part of On-Going Strategic...: Press release article from: Business Wire February 25, 2009 700+ words
...divisions: Biopharmaceuticals and Elan Drug Technologies. Specific adjustments include...the Biopharmaceuticals and Elan Drug Technologies businesses." Dr. Paya said that following the changes, Elan is well positioned in the biopharmaceutical...


Elan Reports Third Quarter 2008 Financial Results.: Press release article from: Business Wire October 23, 2008 700+ words
...shareholders' deficit has no impact on Elan's ability to comply with its...by 85% while revenue from the Elan Drug Technologies (EDT) business increased by 3...performance from Tysabri, with Elan's recorded sales increasing 159...


Elan Reports First Quarter 2009 Financial Results.: Press release article from: Business Wire April 22, 2009 700+ words
...shareholders' deficit has no impact on Elan's ability to comply with its...by 28% while revenue from the Elan Drug Technologies (EDT) business decreased by 14...R]) and Maxipime([R]). Elan's recorded sales of Tysabri increased...


Elan Corp. plc is Added to the Bellwether Watch list.: Press release article from: M2 Presswire June 15, 2007 700+ words
...COMMUNICATIONS LTD RDATE:15062007 Elan Corp. plc (NYSE:ELN) is Added to the Bellwether Watch list Elan Corporation, plc operates as a...segments, Biopharmaceuticals and Elan Drug Technologies. The Biopharmaceuticals segment...


Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage,...: Press release article from: Business Wire November 27, 2007 700+ words
...commented Shane Cooke, Elan's Chief Financial Officer and head of its Drug Technologies business. "We are delighted...capabilities available through Elan Drug Technologies. SODAS is a registered trademark of Elan Corporation, plc AVINZA...

For more facts and information, see all results

Source: HighBeam Research, Elan Announces the Johnson & Johnson Pharmaceutical Research &...

The AccessMyLibrary advertising network includes: